Mika Tsujimoto

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Effects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacy
    Mika Tsujimoto
    Lilly Research Laboratories Development Center of Excellence Asia Pacific, Eli Lilly Japan K K, Sannomiya Plaza Bldg, 7 1 5 Isogamidori, Chuo Ku, Kobe, 651 0086, Japan
    J Bone Miner Metab 30:326-37. 2012
  2. ncbi PINP as an aid for monitoring patients treated with teriparatide
    Mika Tsujimoto
    Lilly Research Laboratories Japan, Eli Lilly Japan K K, Sannomiya Plaza Building, 7 1 5 Isogamidori, Kobe 651 0086, Japan
    Bone 48:798-803. 2011
  3. ncbi Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases
    Akimitsu Miyauchi
    Lilly Research Laboratories Japan, Eli Lilly Japan K K, Sannomiya Plaza Bldg, 7 1 5 Isogamidori, Chuo Ku, Kobe 651 0086, Japan
    Bone 47:493-502. 2010
  4. ncbi Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study
    Akimitsu Miyauchi
    Lilly Research Laboratories Japan, Eli Lilly Japan K K, Sannomiya Plaza Bldg, 7 1 5 Isogamidori, Chuo Ku, Kobe, 651 0086, Japan
    J Bone Miner Metab 26:624-34. 2008
  5. ncbi Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg/day administered subcutaneously in Japanese patients with osteoporosis
    Takanori Yamamoto
    Eli Lilly Japan KK, Sannomiya Plaza Bldg, 7 1 5 Isogamidori, Chuo Ku, Kobe, 651 0086, Japan
    J Bone Miner Metab 31:199-205. 2013

Detail Information

Publications5

  1. ncbi Effects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacy
    Mika Tsujimoto
    Lilly Research Laboratories Development Center of Excellence Asia Pacific, Eli Lilly Japan K K, Sannomiya Plaza Bldg, 7 1 5 Isogamidori, Chuo Ku, Kobe, 651 0086, Japan
    J Bone Miner Metab 30:326-37. 2012
    ..These analyses show that teriparatide clinical data met ICH E-5 criteria for bridging. Findings from foreign trials such as the FPT can thus be extrapolated to Japanese subjects treated with teriparatide 20 μg/day...
  2. ncbi PINP as an aid for monitoring patients treated with teriparatide
    Mika Tsujimoto
    Lilly Research Laboratories Japan, Eli Lilly Japan K K, Sannomiya Plaza Building, 7 1 5 Isogamidori, Kobe 651 0086, Japan
    Bone 48:798-803. 2011
    ..PINP monitoring may be a useful aid in the management of patients with osteoporosis during teriparatide treatment...
  3. ncbi Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases
    Akimitsu Miyauchi
    Lilly Research Laboratories Japan, Eli Lilly Japan K K, Sannomiya Plaza Bldg, 7 1 5 Isogamidori, Chuo Ku, Kobe 651 0086, Japan
    Bone 47:493-502. 2010
    ..These data show that teriparatide 20 microg/day was well tolerated and stimulated bone formation in Japanese subjects with osteoporosis at high risk of fracture during 18 and 24 months of treatment...
  4. ncbi Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study
    Akimitsu Miyauchi
    Lilly Research Laboratories Japan, Eli Lilly Japan K K, Sannomiya Plaza Bldg, 7 1 5 Isogamidori, Chuo Ku, Kobe, 651 0086, Japan
    J Bone Miner Metab 26:624-34. 2008
    ..These results observed in Japanese patients may support the observation that teriparatide stimulates bone formation in patients with osteoporosis at a high risk of fracture...
  5. ncbi Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg/day administered subcutaneously in Japanese patients with osteoporosis
    Takanori Yamamoto
    Eli Lilly Japan KK, Sannomiya Plaza Bldg, 7 1 5 Isogamidori, Chuo Ku, Kobe, 651 0086, Japan
    J Bone Miner Metab 31:199-205. 2013
    ..Additionally, when vitamin D is coadministered, vitamin D insufficiency would not be expected to affect the overall efficacy of teriparatide...